ALT vs JAZZ · rev $20.0K vs P/E 1988, rev $4.07B
Altimmune Inc (ALT) versus Jazz Pharmaceuticals PLC (JAZZ) — a side-by-side from cached financials, not a winner call.
Altimmune Inc (ALT) is a biotechnology company listed on US.
Jazz Pharmaceuticals PLC (JAZZ) is a biotechnology company listed on US.
Latest reported ALT revenue for 2024-12-31 was $20.0K. Net income was -$95.1M. Revenue was down 95.3% from 2023-12-31 to 2024-12-31. ALT currently screens at market cap $527.0M.
Latest reported JAZZ revenue for 2024-12-31 was $4.07B. Net income was $560.1M. Revenue was up 6.1% from 2023-12-31 to 2024-12-31. JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1.
ALT currently screens at market cap $527.0M. JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1.
Not investment advice. Open the ALT and JAZZ stock pages for the full models.
Not investment advice.